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Liposomes can both enhance or 
reduce drugs penetration through 
the skin
Ma. F. Peralta  1, Ma. L. Guzmán2, A. P. Pérez  3, G. A. Apezteguia3, Ma. L. Fórmica2, 
E. L. Romero3, Ma. E. Olivera2 & D. C. Carrer  1
The adequate formulation of topical vehicles to treat skin diseases is particularly complex. A desirable 
formulation should enhance the accumulation of the active drugs in the target tissue (the skin), while 
avoiding the penetration enhancement to be so large that the drugs reach the systemic circulation 
in toxic amounts. We have evaluated the transcutaneous penetration of three drugs chosen for their 
widely variable physicochemical properties: Amphotericin B, Imiquimod and Indole. We incorporated 
the drugs in fluid or ultra-flexible liposomes. Ultra-flexible liposomes produced enhancement of drug 
penetration into/through human skin in all cases in comparison with fluid liposomes without detergent, 
regardless of drug molecular weight. At the same time, our results indicate that liposomes can impede 
the transcutaneous penetration of molecules, in particular small ones.
Liposomes contain three distinct environments for drugs to dissolve in: the water-lipid interface, the hydro-
phobic core, and the aqueous interior. As such, they are useful to dissolve/carry hydrophobic, hydrophilic and 
amphiphilic drugs and antioxidants. This is important since many drugs of therapeutical interest have poor water 
solubilities and/or form unstable solutions.
In the field of topical vehicles for dermal/transdermal delivery, ultra-flexible liposomes are often considered 
the vehicle of choice, mainly because of their high performance as transdermal penetration enhancers and their 
good stability in suspension1–6. Ultra-flexible liposomes are composed by a mixture of lipids with low phase tran-
sition temperatures and an appropriate amount of a detergent. The detergent acts as a membrane destabilizer, pro-
ducing an increase in membrane deformability. Ultra-flexible liposomes high deformability has been proposed 
to be the cause of their ability to penetrate the skin and even allow for proteins to reach systemic circulation7–13. 
However, in the case of diseases where the target tissue is the skin and the active drugs are very toxic to the host 
other organs, it is of high interest to know if ultra-flexible liposomes would be the best choice for treatment. In the 
case of Cutaneous Leishmaniasis (CL) for example, the goal of a topical formulation would be to reach the dermis, 
where the parasites accumulate, but avoid an extensive distribution into the systemic circulation.
The effect of the drugs on (initially) highly flexible liposomes is rarely measured or taken into account. Also, 
the penetration into/through the skin of a drug per se depends on many factors (size, polarity, charge, concentra-
tion in the formulation, temperature, solubility, etc.), and it is almost impossible to predict, based on a molecule’s 
structure and known physical properties, whether it will penetrate the skin or not, at which rate and to which 
extent.
We initially hypothesized that a change in membrane fluidity produced by the incorporation of a drug in 
ultra-flexible liposomes would correlate with a change in penetration. We measured the skin penetration of three 
drugs that possess very different physicochemical properties. AmphotericinB (AmB) is one of the most effective 
drugs for systemic treatment of Leishmaniasis, especially in its liposomal formulation, which diminishes its (very 
serious) side effects. AmB is an amphipathic polyene molecule, with a MW of 924.09 g/mol; it has no formal 
charge; its water solubility is poor, approx. 750 mg/l at 25 °C; its octanol/water partition coefficient logP is 0.8; it 
has a high affinity for membranes and it tends to form aggregates in water14,15. Imiquimod (Imiq) is a nitric oxide 
producer and an immune modulator that has been shown to have a good in vitro activity against some varieties 
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of Leishmania16. Compared to AmB, it has an intermediate size and complexity. Its MW is 240.31 g/mol; it has no 
formal charge; its water solubility is poor, approx. 247 mg/l at 25 °C; its logP is 2.717. Indole (Ind), to the best of 
our knowledge, has not yet been tried against Leishmania. Some of its derivatives show promising results against 
some forms of the parasite18. Ind has been proven to be an important modulator of the immune system19, and 
we have obtained promising results against L. Amazonensis in vitro (Peralta et al., unpublished results). Ind is an 
aromatic bicyclic compound; it has a small size and complexity compared to AmB and Imiq. Its MW is 117.15 g/
mol; it has no formal charge; its water solubility is good, approx. 3,560 mg/l at 25 °C; its logP is 2.1420. In summary, 
we have studied the penetration of one big, complex, insoluble drug (AmB); one medium-sized, relatively simple, 
insoluble drug (Imiq) and one small, simple, soluble drug (Ind).
We incorporated the drugs either in SoyPhosphatidylcholine:NaChol (SPC:NaChol) (ultra-flexible) or SPC 
(fluid but not ultra-flexible) liposomes. We measured the penetration both of lipids and of drugs from these 
systems into mouse skin in vivo and human skin in vitro respectively; evaluated the effect of the drugs on the 
liposomes deformability; and measured drug penetration from ultra-flexible or fluid liposomes.
Results
Liposomes show size stability. After extrusion, empty liposomes showed an average diameter of 100 nm. 
The addition of Imiq, AmB and Ind in a mol ratio of 10:1 lipid:drug did not significantly change the diameter 
of liposomes immediately after extrusion, nor a second population with a different size appeared in the samples 
(Fig. 1). All liposomes maintained their diameter over the assayed period of 21 days.
Indole increases liposomes deformability. Deformability of the liposomes (empty fluid and ultra-flexible, 
ultra-flexible with drugs at 10:1 mol:mol lipid drug relation) is shown in Fig. 2. NaChol produces an important 
increase on the deformability of the membrane21. Ind increases the deformability of the ultra-flexible liposome 
membrane, while the incorporation of Imiq does not produce a significant difference (p ≤ 0.05). This parameter 
could not be measured on ultra-flexible liposomes containing AmB since the dispersion did not pass through the 
membrane at the pressure used (1 MPa).
In vitro human skin penetration/retention varies greatly. The methods used for extraction and quan-
tification of drugs in human skin were assessed for linearity, precision and accuracy (Supplementary Table S2). 
The methods were accurate, precise and reproducible. Variation coefficients were less than 15% in all cases. 
Recovery percentages are also shown in Supplementary Table S2.
All the assayed drugs, from liposomal suspensions as well as from aqueous solutions/suspensions, reached 
the dermis. However, Kp (permeability coefficient) can only be determined when the assayed drug reaches the 
receptor compartment of the Franz cell in measurable amounts. This condition was only met in the samples 
incubated with Ind.
Figure 3 shows the amount of drug recovered in the different skin layers after 24 hs incubation. As can be 
observed, when Ind penetration was assessed from ultra-flexible liposomes suspensions, its skin concentration 
was higher in comparison with its reference solution, with most of the drug being found in the dermis (1.5% of 
the total amount applied in epidermis (E) and 22.2% in dermis (D)). Ind from fluid liposomes suspensions pen-
etrated in a lower proportion in comparison with Ind in ultra-flexible liposomes suspensions. The permeability 
coefficient for Ind from ultra-flexible liposomes suspensions was 55.4 ± 0.4 E−05 cm−1, while Kp for Ind in HEPES 
was 63.4 ± 0.3 E−05 cm−1. Ind from fluid liposomes suspensions reached the receptor medium only in the last 
hour of the assay test, and so it was not possible to calculate Kp in this case. These Kp values indicates that Ind 
Figure 1. Diameter of liposomes containing different drugs as a function of time. Samples were prepared on 
day 0, kept at 4 °C and measured every two or three days by Dynamic Light Scattering. The results are the mean 
of measurements from three independent samples.
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in buffer reaches the receiving compartment in larger amounts compared with ultra-flexible and fluid liposomes 
suspensions.
When incorporated in ultra-flexible liposomes suspensions, Imiq penetrated moderately into the skin, with 
most of the drug being found in the epidermis (8.5%) and a significant amount found in the dermis (3.4%) 
(Fig. 3). The skin penetration percentage of Imiq from ultra-flexible liposomes suspensions was not significantly 
different from its buffer suspension; however both occurred in a higher proportion in comparison with fluid 
liposomes suspensions. Since Imiq did not reach the receptor compartment, it was not possible to calculate Kp.
The penetration of AmB into the skin occurred in the order aqueous suspension» ultra-flexible liposomes 
suspensions > fluid liposomes suspensions (Fig. 3). AmB penetrated to a significant amount when applied as 
a suspension in buffer to the surface of the skin (6.4% found in dermis and 33.6% in epidermis). When incor-
porated into ultra-flexible liposomes suspensions, AmB was mostly retained in the epidermis, with a very small 
Figure 2. Liposomes deformability measured by extrusion. Deformability was calculated according to D = J × 
(rv/rp)2, were J is the phospholipids flux, rv is the vesicle size after the assay and rp is the pore membrane size. 
Results are shown for empty fluid and ultra-flexible liposomes, and for ultra-flexible liposomes containing the 
different drugs.
Figure 3. Drugs retention in human epidermis and dermis in vitro. Drug retention is quantified as percentage 
of donor formulation (initial amount). Statistical analysis was performed with ANOVA, P ≤ 0.05.
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amount found in the dermis (1.9% and 0.9% respectively). From fluid liposomes suspensions it was retained in a 
very small amount in the epidermis (0.1%) and did not reach the dermis.
Figure 4 shows the penetration profile of each of the drugs in human skin. Except for the case of Ind, the 
drugs were found in higher quantities in the first microns of the skin, near the surface. AmB from fluid liposomes 
suspensions was mostly retained on the surface of the skin (Fig. 4A) and penetrated only to 12.5% of the skin 
thickness from the surface. However, when incorporated into ultra-flexible liposomes suspensions it was present 
in measurable amounts up to 80% of the skin thickness, meaning it penetrated the whole epidermis and reached 
the second third of the dermis. When applied as an aqueous suspension, AmB was found at all depths of the skin 
and the total amount found in the skin was higher than in the liposomal formulations.
Imiq penetration depth from ultra-flexible liposomes suspensions was highest in the first 46% of the skin 
thickness. Imiq from aqueous suspension was found mainly in the first 50% of the skin depth. Imiq penetration 
from fluid liposomes suspensions was the lowest in comparison with both liposomal and aqueous suspension, 
with most of the drug being found in the first 20% of skin depth (Fig. 4B).
Ind showed a very different profile compared to AmB and Imiq. It was found in higher amounts in the deeper 
strata of the skin than near the surface. Ultra-flexible liposomes allowed for a higher penetration of Ind in the 
skin, with most of the drug being found in the deepest parts of the dermis. When incorporated into fluid lipos-
omes suspensions, Ind was retained in similar amounts in all the dermis. Ind in solution shows a peak of retention 
near the end of the dermis, at 80% of total skin depth, but shows the least amount of drug retained in the skin.
Liposomes with different drugs penetrate to a similar extent into mouse skin in vivo. Figure 5 
shows a typical fluorescence confocal microscopy image of mouse skin incubated with fluorescent liposomes. The 
lipidic fluorescent analogue becomes enriched in the furrows (canyons) that separate and envelop the corneocytes 
clusters.
The epidermis of mice, pigs and apparently also humans is organized in corneocyte columns, with polygonal 
shapes9,10,22. Each column or “cluster” of cells is surrounded and separated from others by a structure called a 
“canyon”. The canyons seem to be invaginations or extensions of the stratum corneum, which reach the epider-
mis/dermis interface. They start as a superficial wrinkle and then close, reaching the stratum basal. Canyons are 
a preferential channel for transepithelial penetration of hydrophobic molecules10.
Figure 4. Amount of drug found by HPLC at different layers of human skin ex-vivo. Drug amount is shown 
as percentage amount from donor (formulation put on the skin) versus percentage of skin depth. ●Drug in 
solution/suspension. ■Drug in ultra-flexible liposomes. ▲Drug in fluid liposomes.
www.nature.com/scientificreports/
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Figure 6 shows the fluorescence intensity of the lipidic probes incorporated into ultra-flexible liposomes sus-
pensions containing the different drugs at the different depths of the skin, in canyons and clusters respectively. 
Liposomes penetrate mostly through canyons and in fewer amounts through clusters. Liposomes penetrate until 
15 microns through clusters and 30 microns through canyons. Mouse skin has an epidermis of 15 microns thick-
ness, with 6 microns of stratum corneum. Therefore, all dispersions are able to penetrate the epidermis by clusters, 
and reach the dermis by canyons.
There are no significant differences between formulations containing different drugs, although the liposomal 
suspension with AmB seems to be more retained in the epidermis than the other formulations.
Discussion
Pharmaceutical actives frequently have a poor stability, are not well absorbed, are systemically toxic and are 
hard to transport to the action site. To solve these problems, nanoparticulated carriers like liposomes have won 
increasing interest23. Properly formulated liposomes form suspensions that are stable in size and do not precipi-
tate; liposomes can easily incorporate/aid in the epidermal penetration of drugs of very variable physicochemical 
properties, they can incorporate lipophilic antioxidants, usually indispensable for formulation stability; lastly, as 
discussed below, the presence of liposomes allows for a modulation of the drugs penetration/retention into the 
skin.
The case of skin diseases is particularly complex. A desirable formulation should be able to enhance the accu-
mulation of the active drugs in the target tissue, while avoiding the skin penetration enhancement to be so large 
that the drugs reach the systemic circulation in amounts that may be toxic. In the particular case of Cutaneous 
Figure 5. Confocal fluorescence microscopy image of mouse skin. In blue, autofluorescence of the skin 
(excitation at 405 nm, emission collected at 520–550 nm); in pink, fluorescence of the lipidic dye incorporated 
in liposomes (excitation at 543 nm, emission collected at 550–630 nm). Two different structures are visible: 
canyons (invaginations of the stratum corneum) and clusters (groups of corneocytes). The asterisk indicates a 
wrinkle. The yellow bar indicates 25 μm.
Figure 6. Quantification of ultra-flexible liposomes penetration into mouse skin in vivo. Liposomal lipid 
tracing trough canyons (a) and trough clusters (b) at different depths in mouse skin. Fluorescence intensity of 
DiIC18 (fluorescent lipid analogue incorporated into the liposomes) was quantified in micrographs taken by 
confocal microscopy at planes parallel to the skin surface every two microns. ●Ind-containing ultra-flexible 
liposomes. Δ Imiq-containing ultra-flexible liposomes. ▲ AmB-containing ultra-flexible liposomes. □ Empty 
ultra-flexible liposomes.
www.nature.com/scientificreports/
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Leishmaniasis, the target tissue is the dermis, and the drugs that show activity against Leishmania are extremely 
toxic to liver, kidneys and bone marrow. Topical formulations containing these drugs are thus of high interest 
from a clinical perspective.
Drugs penetration through the skin depends on a great variety of factors. One of them is the pathway that 
drugs take to penetrate into the dermis. The biggest barrier to penetration of the skin is the stratum corneum 
(SC). This skin structure has a “brick and mortar” organization of corneocytes (the “bricks”, mainly composed 
of hydrated keratin) and multilamellar layers of ceramides, fatty acids, cholesterol and cholesterol esters24 (the 
“mortar”). These bilayers contain domains in gel and liquid crystal phases and are very hydrophobic, with very 
long chains, low hydration and high melting temperatures25,26. We and others have shown that the epidermis as a 
whole is organized into clusters or columns of cells, separated from each other by furrows (“canyons”) filled with 
lipids that traverse the entire epidermis, reaching the basal layer near the dermis. The lipids in these structures 
have physical properties very similar to those of the stratum corneum, and so we have hypothesized that the can-
yons may be invaginations of the SC10,27. As we show in this manuscript, the lipids from the liposomes penetrate 
deeper through the canyons than through the cell clusters. It may be possible that some drugs, especially the most 
hydrophobic drugs, would follow them since the lipidic environment would facilitate lipid-lipid/drug-lipid inter-
actions. Further, the viable layers of the skin (in the clusters, below the SC) can metabolize the drugs, impeding 
their penetration.
Other important factors that affect drug penetration are: the molecular weight of the molecule, which should 
be below 600 Da for a good penetration; the solubility of the molecule in oil vs. water (the penetration has been 
proposed to depend parabolically on logP, with a maximum at a logP of 328). Also the concentration of drug in 
the donor solution (a larger concentration gradient will produce a larger flux); the charge of the molecule, where 
charged molecules have a much larger thermodynamic barrier for penetration. An excess of drug in a solution 
will produce its precipitation in the form of crystals, with a maximum thermodynamic activity at the surface of 
the skin that will increase the flux but can be irritant and is highly inconvenient for the stability and homogeneity 
of the pharmaceutical formulation.
The incorporation of liposomes avoids the crystallization of insoluble drugs by dissolving them in a lipid 
matrix. The physicochemical properties of the vehicle lipids are also important: liquid state vesicles penetrate 
deeper than gel state liposomes29, and highly elastic vesicles facilitate transport across the skin better than rigid 
or fluid liposomes13.
Liposomes of SPC and NaChol are ultra-flexible and its lipidic components are capable of penetrating to the 
epidermis/dermis interface10. Their penetration enhancement capability seems to depend strongly on the deform-
ability of the liposomal membrane30.
Ind increases liposome deformability, while Imiq does not have a measurable effect and AmB could not be 
measured at the concentration used. Other authors, using a much lower concentration of AmB, have measured 
the deformability of similar liposomes31, obtaining D values between 500 and 1600, i.e. a diminished deformabil-
ity in the presence of the drug. The drug penetration and retention in the skin when incorporated in ultra-flexible 
liposomes suspensions follow the order Ind > Imiq > AmB. This penetration capability correlates with the 
deformability results obtained or shown in the literature. However, we found that focusing only in the flexibility 
of the liposomes was not enough to explain all the results obtained.
In our experiments we did not remove the free drug outside the liposomes. The mechanism of action of 
liposomes applied to the skin remains a matter of debate. Some authors claim that the liposomes can act as 
carriers, penetrating intact through the skin, while others propose that liposomes act as penetration enhancers, 
changing the skin physical properties in a way that facilitates its penetration by the drugs. Honeywell-Nguyen and 
Bouwstra propose that elastic vesicles carry vesicle-bound drugs into the SC by a fast partitioning, and then the 
vesicles remain in the SC while the drug continues to the deeper skin layers32. Others found that liposomes modu-
late the penetration not only of the entrapped drugs but also of non-entrapped drug33,34. Subongkot et al. propose 
that vesicles could traverse the skin intact through follicular channels35. Our experience leads us to support a 
version of the proposal by Honeywell-Nguyen and Bowstra, namely that liposomes, once applied on the skin, 
rupture and diffuse as a lipidic mixture that acts as a penetration enhancer. Follicular channels may be a way of 
penetration for intact liposomes, but at least in the case of humans it would not be a major way of penetration. The 
liposomes are able to modulate the penetration of the drugs, and their physical characteristics and composition 
are very important, but they do not penetrate the skin as the original vesicles that we prepare. In this scenario, it 
is not necessary to remove the free drug, since once the formulation interacts with the skin, all molecules present 
mix with those of the SC, and the fluidization of the skin lipid membranes produced by the components of the 
liposomes enhances the penetration of all drug molecules present, regardless of their being initially in the liposo-
mal membrane, the liposomal aqueous interior or the aqueous buffer outside the liposomes.
The in vivo experiments in mice show that liposomal lipids penetrate until 20 µm, reaching the dermis, inde-
pendently of the drug present. So apparently the lipids can influence the drugs penetration but the opposite is not 
true, at least in this case. In terms of interaction with the skin structure, lipids penetrate more and deeper through 
canyons than through clusters. This observation coincides with previous reports10,30. The added drugs did not 
change this preference.
In the in vitro experiments, we used buffer solutions of the drugs with the intention of having controls for 
the effect of liposomes on penetration. In the case of Ind, the drug dissolves completely and we get a solution; 
however, AmB and Imiq have very poor solubilities in water and, at the concentrations used, form suspensions in 
which the solid particles are surrounded by a layer of saturated solution. The activity of the drugs in the solid par-
ticles and in this solution layer is the highest possible24, and this would explain why AmB and Imiq in suspension 
penetrate more than in liposomal formulations, where the drugs are well dissolved and homogeneously dispersed 
but mixed with the liposomes components, therefore having the same overall concentration but a lower activity. 
For this reason, it is not possible to directly compare the penetration of the drugs suspensions in buffer with the 
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liposomal samples. The aqueous suspensions are rather extra samples to analyse. Thus we do not know precisely if 
the liposomes enhance the penetration of AmB and Imiq or not, but they undoubtedly allow for the formulation 
of stable suspensions containing high concentrations of hydrophobic drugs without the need of using organic 
solvents. The two drugs in these stable liposomal formulations are able to penetrate to the dermis.
AmB, the largest of the molecules studied, penetrated into the skin best when applied as an aqueous suspen-
sion and penetrated very little when applied in fluid liposomes. The amount found in the skin follows the order 
aqueous suspension ≫ ultra-flexible liposomes suspension > fluid liposomes suspension.
The penetration of Imiq, of intermediate size, showed intermediate penetration results (see Fig. 7). The 
amount of drug that penetrated into the skin followed the order aqueous suspension ≈ ultra-flexible liposomes 
suspension > fluid liposomes suspension. In this case we expected to find again that the aqueous suspension 
penetrated more than the drug in liposomes. However this was not the case. The high flexibility of the liposomes 
containing NaChol may have balanced the effect of the lowering of the activity of the drug produced by its dilu-
tion with lipids and detergent. The fluid liposomes however produced a lowered penetration. Other authors have 
shown that Imiq penetration is very low, and it depends specifically on the vehicle. Saturated solutions of Imiq in 
different solvents (different final concentrations) show similar penetration rates36.
The penetration of Ind, the smallest drug tested, is strongly determined by its molecular weight. It is well 
known in the literature that small molecules can penetrate the skin more easily, with a cut-off of approximately 
600 g/mole37,38. Indeed, Ind was the only molecule that reached the receiving compartment in measurable 
amounts. It was surprising to find that the presence of liposomes hindered the penetration of Ind as compared 
to the solution in buffer, even in the case of ultraflexible liposomes. Ultra-flexible liposomes allowed for a larger 
amount of drug to be retained in the skin compared to the aqueous solution (26% of Ind from liposomal suspen-
sion against 13.4% of Ind in buffer). 57% of the applied drug in buffer was found in the receiving compartment of 
Franz cells after 24 hs, while from ultra-flexible and fluid liposomes suspensions 50% and 32% were found in this 
compartment respectively. Also the kinetics for drug penetration was different for each formulation. For example, 
after 8 hs incubation, the amount of Ind that reached the receiving compartment was 27%, 14% or 0% with buffer 
solution, ultra-flexible liposomes and fluid vesicles respectively (Fig. 7). Thus, liposomes, including ultraflexible 
liposomes, slowed down Ind penetration.
This retention of Ind in the skin may be produced by molecular interactions (van der Waals, cation – π inter-
actions and hydrogen bonding39) occurring between the lipids from the liposomes, the skin lipids and the drug. 
If the affinity of the drug to the vesicle lipids is high and the solubility in the SC lipids is low, then the liposomes 
could slow down the penetration of the drug32.
In summary:
•	 Drugs from ultra-flexible liposomes suspensions penetrate deeper and in larger quantities than from fluid 
liposomes irrespective of the drug’s molecular weight.
•	 The penetration of the drugs from ultraflexible liposomes correlates well with the changes in flexibility 
observed, produced by the inclusion of the drugs.
•	 Aqueous suspensions of insoluble molecules penetrate better than ultra-flexible liposomes suspensions when 
the drug is very large (AmB), but similarly to ultra-flexible liposomes suspensions when the drug is of inter-
mediate size (Imiq).
•	 In the case of a soluble drug with a MW < 600, the drug penetrates more when it is in solution, being able to 
reach the receiving compartment. Its incorporation into liposomal suspensions hinders and slows down its 
penetration, in particular, ultra-flexible liposomes allow the drug to become more enriched in the skin.
Figure 7. Drug delivery from different vehicles in human skin. ‘Drug in buffer’ stands for a suspension (for 
AmB and Imiq) and for a solution in HEPES buffer in the case of Indole. 8 and 24 hs indicate incubation times. 
E: epidermis; D: dermis; R C: receiving compartment. The coloured areas are proportional to the amount of 
drug found in each stratum of the skin or receiving compartment.
www.nature.com/scientificreports/
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Conclusions
Ultra-flexible liposomes enhance the penetration of the three drugs, irrespective of the drug’s size, compared to 
fluid liposomes (see scheme in Fig. 7). On the other hand, when comparing a small soluble drug in solution (Ind) 
with the same drug in the presence of liposomes, the effect of liposomes is not to enhance penetration but rather 
to retain the drug in the skin. We do not know which mechanisms are at play, but ultra-flexible liposomes allow a 
higher amount of drug to be retained in the skin while fluid liposomes slow down Ind diffusion into the skin. This 
slowing down of diffusion is also seen on the results from Imiq, where the drug from fluid liposomes penetrates 
the least into the skin. This information suggests that liposomes can either enhance or reduce skin penetration, 
depending on the molecular weight of the drug and the liposome composition. This may prove of importance 
when the intention of the formulation is for the drug to stay in the skin rather than reach the blood stream, which 
is precisely the case when developing a formulation for topical treatment of a skin disease.
Materials and Methods
L-α-Phosphatidylcholine of Soy (purity >99%) was purchased from Avanti Polar Lipids, Alabama, USA. Sodium 
Cholate, Indole, Imiquimod and AmphotericinB were from Sigma Aldrich, St. Louis, USA. SnakeSkin® Dialysis 
Tubing, 3.5 K MWCO was purchased from Thermo Scientific, USA. Methanol and chloroform were from Emsure, 
Germany. HEPES was from AppliChem, Germany. All other reagents were of analytical grade. For HPLC meas-
urements, methanol and acetonitrile (Anhedra®) were HPLC quality. Absolute ethanol (Sintorgan®) and dietila-
mine (Anedra®) were FVpharmaceutical grade. For mobile phases, monobasic potassium phosphate and sodium 
acetate (Ciccarelli®) pharmaceutical grade were used. All experiments were done with Milli-Q water.
Liposome preparation. Three different formulations were prepared with the following drugs: 
AmphotericinB, Imiquimod and Indole. Liposomes of SPC containing NaChol are called “ultra-flexible” due 
to their very low resistance to out-of-plane deformability13,40. Ultra-flexible liposomes of SPC:NaChol:drug in a 
molar ratio of 10:3:1 were prepared by thin-film hydration. Appropriate amounts of SPC in chloroform:methanol 
(2:1 v/v) and NaChol in methanol were mixed in a glass flask. Solutions of Imiq and AmB were added in this step. 
AmB was dissolved in DMSO:methanol (1:9 v/v); Imiq in acetonitrile:HCl (100:1 v/v). Solvents were evaporated 
by a nitrogen flux followed by vacuum for at least 4 hours. The resultant thin-lipid film was hydrated with HEPES 
buffer 30 mM, pH 7.4 up to a final lipid concentration of 50 mg/ml. This liposomal dispersion concentration was 
selected for all the following experimental sections. Ind solution was added in the hydration step. Liposomal dis-
persions were extruded 17 times through a 100 nm pore polycarbonate membrane using a 1 ml extruder (Avanti 
Polar Lipids, Inc., Alabama, USA) at room temperature. Free drug outside the liposomes was not removed. See 
the Discussion for an explanation of this choice of method.
Liposome size and physical stability. All liposomal dispersions were stored at 4 °C and the average lipos-
ome diameter was measured every two days for 21 days by Dynamic Light Scattering (Submicron Particle Size 
NICOMPTM 380, California, USA). For these measurements, samples were diluted in HEPES buffer at a final 
concentration of 1.6 mg/ml of lipid. Experiments were performed three times independently.
Deformability measurements. Deformability of liposomes was determined according to Van der Bergh 
et al.41. This method is based on the fact that membrane liposome deformability is proportional to its penetra-
tion capability through a permeability barrier. An aliquot of 2 ml of each of the drug’s liposomal formulations 
was extruded (Thermobarrel, Northern Lipids, Burnaby, Canada) at room temperature through 50 nm pore size 
polycarbonate filters, at a constant pressure of 1 MPa applied with external N2. The extruded volume was collected 
every minute for 15 minutes and phospholipids from liposomes were quantified in each fraction by a colorimetric 
assay42.
Deformability was calculated according to eqn (1):
= ×D J (rv/rp) (1)2
where J is the phospholipids flux (area from phospholipid percentage vs. time plot), rv is the vesicle diameter after 
the assay (measured by Dynamic Light Scattering with a NanoZsizer) and rp is the pore membrane size (50 nm). 
Ultra-flexible liposomes without the addition of drugs (empty liposomes) and liposomes without detergent (fluid 
liposomes) were used as references. Experiments were performed three times independently.
In vitro human skin penetration. In order to evaluate the skin penetration of AmB, Imiq and Ind, assays 
were performed through abdominal human skin portions in diffusive Franz-type cells (N = 5, i.e. skin from 5 
different people) at 36 °C. Human skin was obtained by a plastic surgeon during dermolipectomy surgeries at 
a local hospital. We worked with discard skin material (procedure approved by Hospital Privado Health Ethics 
Committee HP 4-158). All experiments were performed in accordance with Consejo de Evaluación Ética de la 
Investigación de la Salud, CoEIS (Health Ministry of the Province of Córdoba) guidelines and regulations and 
in compliance with Provincial Law 9694. No information concerning patient’s identity was disclosed to us at any 
stage, either in coded or uncoded form. The Hospital Privado Health Ethics Committee waived the need to obtain 
informed consent for the use of these samples. All samples were entirely discarded after analysis. This research is 
therefore not considered as human subject research. For the assays, the skin was separated from the underlying 
fat tissue with a scalpel. Skin portions were stored at −20 °C no longer than 30 days. Before assaying, skin pieces 
were thawed at room temperature. A volume of 180 µl of each dispersion was added on the skin in the donor 
compartment, with an exposed area of 1.3 cm2. Drugs were loaded in ultra-flexible liposomes suspensions. Fluid 
liposomes and HEPES buffer solutions (for Ind) or suspensions (for AmB and Imiq) at equivalent concentrations 
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were used for comparison. In order to reach sink conditions, the receptor compartment (16 mL) was filled with 
phosphate buffered saline (PBS) pH 7.4 containing sodium 1% lauryl sulphate for experiments with AmB and Ind 
and 10% ethanol for the experiments with Imiq43.
To determine drug permeation rate through the skin, 1 ml samples from the receptor medium were collected 
after 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours, with fresh medium replacement. Permeability coefficient Kp was determined 
by eqn (2):
=K J /C (2)p ss 0
where C0 is the drug initial concentration in the donor compartment (liposomal suspensions on the skin). 
Stationary drug flux (Jss, µg/cm2/h) was calculated from the relation between the slope of the quantity of perme-
ated drug vs time plot and the area exposed (1.3 cm2)44.
After 24 hs, the skin was removed and processed to determine: (1) the amount of drugs retained in the epi-
dermis (E) as well as in the dermis (D) (expressed as percentage of donor drug amount, see eqn (3); (2) the pen-
etration depth (plotted as the percentage of the donor compartment drug amount penetrated vs percentages of 
the total skin thickness).
µ
µ
= ×retained g drug in D or E
g drug in donor
100%
(3)
After incubation in Franz cells, the skin was rinsed with distilled water, dried with paper and divided in two 
parts of similar size (parts A and B), which were weighed and processed. Part A was used for the retention assay 
in order to quantify epidermis and dermis drugs content. For this purpose, specific methodologies were validated 
according to Supplementary Table S1. Epidermis was separated from dermis by heating at 60 °C in a stove for 
5 minutes and peeling off with tweezers. Part B of the skin was used for penetration depth assay: skin was cut with 
a cryostat every 60 microns and pooled in groups of 6 cuts. Drugs content were determined after their extraction 
according to Supplementary Table S1.
For penetration depth plots, drug amount is shown as percentage from donor (amount of drug incorporated 
into each formulation applied on the skin) against the percentage of the total thickness of each of the skin samples 
studied. The total thickness of the skin samples varied from 2,200 to 3,600 microns.
Drug extraction from skin and validation of quantification method. In order to quantify each 
of the drugs retained in the dermis and epidermis, the extraction and quantification were validated by HPLC. 
Chromatography was performed using a Waters® HPLC system equipped with a 1500 HPLC pump, a 717 auto 
sampler and a Waters 2996 PDA detector. Data acquisition and processing were performed using Empower® 
system software. The temperature was maintained with a Waters 1500 series column heater at 25 °C or 38 °C 
depending on the drug.
Extraction and quantification methods used for each drug and skin portion are summarized in Supplementary 
Table S1. Linearity, specificity, recovery, precision, accuracy and lower limit of quantification were determined 
for each method. Samples were prepared as described below. Each value is expressed with its relative standard 
deviation (%RSD)45.
A stock solution of each drug was prepared and then diluted with methanol. AmB was dissolved in DMSO 
(2.5 mg/ml) and diluted to 5, 10, 50, 100 and 500 µg/ml for epidermis experiments; or to 5, 25, 35, 50, 100 and 
250 µg/ml for dermis experiments. Ind was dissolved in HEPES buffer pH 7.4 (1.6 mg/ml) and diluted to 30, 50, 
70, 140 and 300 µg/ml for epidermis experiments or to 25, 70, 250, 500, 750 and 1500 µg/ml for dermis experi-
ments. Imiq was dissolved in acetonitrile (1.64 mg/ml) and diluted to 10, 20, 50, 100 and 500 ng/ml for epidermis 
extractions or to 5, 10, 25, 50 and 250 µg/ml for dermis extractions. An aliquot of 20 µl or 10 µl of these solutions 
were added to dermis or epidermis segments respectively (skin portions of aprox 0.5 cm2), in triplicate. After 2 hs 
at room temperature, extraction methods described in the Supplementary Table S1 were tested.
In vivo skin penetration in mice. In vivo skin penetration of the lipidic components from the liposomal 
dispersions was studied in female BalbC mice (8 weeks old) by confocal fluorescence microscopy. The aim of 
this experiment was to follow the lipids of the liposomes dispersions through the different structures of the skin 
(canyons, clusters, dermis), and to see if incorporation of the different drugs had any effect on penetration depth 
or preferred way of penetration through the skin. The liposomal suspensions were prepared as before, but with the 
addition of 1 mol % DiIC18 (a fluorescent lipid analogue) in choloroform:methanol (2:1) to the initial mixture of 
lipids. The animals were anesthetized (ketamine:xylazine:NaCl 0,9% 5:18:77, 200 µl per animal); the hair on their 
back was carefully cut with a hair cutting machine and an aliquot of 20 µl of each liposomal suspension was added 
to 1 sq. cm of exposed skin (see Supplementary Fig. S1). Thereafter the animals were maintained in a temperature 
(20–24 °C) and humidity (40–70%) controlled room with free access to autoclaved diet and water, subjected to 
12 h dark/light cycles.
Twenty four hours after administration, animals were sacrificed by anaesthesia + cervical dislocation. The 
skin was carefully shaved to eliminate the remaining hair, excised and mounted on a glass slide, without fur-
ther treatment, with the dermal side in contact with a piece of paper wet with buffer to avoid skin drying dur-
ing imaging. Confocal images 512 × 512 µm size were taken immediately every two microns with a Confocal 
Olympus Fluoview 1000 Spectral microscope. The objective used was a PLAPON 60X O NA:1.42. The 543 nm 
line of a HeNe laser was used to excite the lipidic dye. The fluorescence was collected between 550 and 630 nm. 
On each animal, two different formulations were tested, with a total of 6 sites of application on each mouse (see 
Supplementary Fig. S1). Seven experiments were performed for each liposomal dispersion (total n = 21). Ten 
different locations on each skin sample were investigated. On each image, the area comprising the clusters or 
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the canyons was selected by hand. The fluorescence intensity from each area was measured. Image analysis was 
performed with Fiji ImageJ.
Animal experimental procedures were approved by the Institutional Committee for Care and Use of 
Experimental Animals regulation (Instituto de Investigación Médica Mercedes y Martín Ferreyra, Res. N° 
013/2017A). The procedures comply with the National Institutes of Health guide for the care and use of 
Laboratory animals (NIH Publications No. 8023, revised 1978).
Statistical analysis. Statistical analyses were performed with ANOVA one way, p was ≤0.05 in all cases. For 
this test, normality was checked by Shapiro Wilks method; variance homogeneity was checked by Levenne test 
and independency is assured since all samples were freshly prepared. The software Infostat was used. Results are 
informed as mean and standard error.
Data Availability Statement
All information necessary for conduction of experiments is included in this manuscript and/or in the supporting 
information.
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